[
  {
    "path": "posts/2021-09-15-blog-post-2/",
    "title": "Serbia, A Middle Income Vaccine King",
    "description": "Looking at how Serbia has destroyed the vaccine roll out game.",
    "author": [
      {
        "name": "Harriet Mason",
        "url": {}
      }
    ],
    "date": "2021-09-15",
    "categories": [],
    "contents": "\r\nI Heard Serbia is Doing Well With the Whole Vaccine Thing…\r\nSerbia did such a good vaccine roll out, they made the Australian government look more like steaming garbage. They gave everyone vaccines and then had extra for people crossing the border, so long as they had a booking and were willing to take the vaccines nobody else wanted (Stanisljevic). One of the reasons Serbia has been considered to have a good vaccine roll out is because it was a middle income country that has already managed to have a pretty large percentage of its population fully vaccinated. This makes me interested in two factors that I will investigate here:\r\nWhich Vaccines are the Most Popular In Serbia?\r\nHow much does an income factor into how vaccinated a country is, and is Serbia really ahead for middle income countries?\r\nMost Popular Vaccines\r\nSerbia has a vaccine catalogue of AstraZeneca, Pfizer, Sinopharm, and Sputnik. Data on the number of people getting vaccinated by each brand is rather hard to find, and by rather hard to find I mean I couldn’t find it. Since the data is not directly available, I wonder if the answer to this question will appear in other places, i.e. the Google Trend data. Therefore, the relationship between vaccine searches and vaccines administered is what I’m going to investigate here. Unfortunately the google trend data does not lend itself well to comparison. Either for interpretability reasons or because Google has some twisted fantasy where their data is impossible to use, Google Trend data is on a scale from 0 to 100 on how popular that search term is relative to itself. Ultimately this means that the only way we can see if a vaccine was popular is to check if spikes in the search term line up with spikes in vaccination, which I’ll try to look for with the plot below.\r\n\r\n\r\n\r\nSince the trends are relative to themselves, vaccine searches with a high amount of noise are likely to be lower in “total searches”. Therefore the search volume order likely goes AstraZeneca, Pfizer, Sinopharm, and then Sputnik. Interestingly it looks like despite Sputnik maintaining continuous small amounts of interest, it did not influence many vaccinations. An initial spike in Pfizer and Sinopharm searches aligns with the first spike in vaccine doses, and a second spike with AstraZeneca and Pfizer had another spike in vaccine numbers a little later. Ultimately the noisy vaccine data also indicates there is likely lagging in reporting which could also be causing the peaks in vaccinations, so these conclusions could have some weight in them, but are also just as likely to be spurious. Does a lack of results mean this was a waste of our time? No, because negative results are just as important as positive ones (no positive results bias to be found in this blog). It doesn’t matter what vaccine people get anyway, as long as they get one at all. With that in mind, lets see how Serbia compares to the rest of the world in their current vaccination rate.\r\nGlobal Politics and Vaccine Roll outs\r\nSerbia’s is considered to be a success story of a middle income country getting a diverse vaccine portfolio, and translating that into an effective roll out. To see how it compares to the rest of the world, we are going to look at an interactive bubble plot that compares each countries number of vaccinations per 100 people to the total number of Covid-19 cases per 100 people. Since most vaccines need two does, we would consider a fully vaccinated population o have 200 doses per 100 people. The size aesthetic will be cases per 100 people to see if the number of cases is more strongly related to the vaccine roll out than GDP.\r\n\r\n\r\n{\"x\":{\"data\":[{\"x\":[5.1,56.7,22.8,120.9,7.5,null,81.1,104.1,11.3,140.1,89.8,119.5,76,44,148.6,21.4,75.9,32.8,142,64.8,1.4,133.7,135.5,53.8,32.3,24.4,101,106.6,86.5,35,0.8,125.9,1.7,143.6,66.3,null,155.3,2.3,0.6,158.6,153.8,73.6,38.5,5.6,0.1,95.6,6,82.4,145.9,118.4,93.2,109,149.1,6.6,60.3,105.9,115.2,11.2,108.1,26.1,99.1,18.1,2.9,null,147,101.8,130.8,136.1,83.7,6.6,8.4,41.3,125.7,4.1,234.4,109.7,130.7,42.8,33.8,null,10.5,1.6,65.1,0.4,46.8,94.9,147.2,54.5,42.7,41.7,14.3,141.3,150.9,158.2,136.7,21.9,117.3,null,65.9,69.7,5.8,24.4,55.6,19.6,60.5,82.3,38.6,9.4,2.2,19.2,115.9,117.6,123.3,1,5,121.2,131.9,1.8,153.6,6.6,125.7,71.9,51.3,125.5,133.1,67.8,null,98.3,7.7,11.5,13.9,38.2,127,55.9,87.4,11.1,2.6,2.8,67.1,138.5,79,31.9,34.8,114.8,1.5,59.9,63.9,36.1,97,150.7,160.2,51.2,59.7,21.8,71.9,138.2,26.1,115,10.4,147.9,2.8,159.2,118.9,84.6,94.7,13,2.1,25.6,104.2,0.6,144.9,110.5,87.8,35.1,29,2.9,63.2,128.1,115.1,2.3,null,36.1,0.6,57.7,46.7,7.9,71.3,58.5,122.1,131.4,3.1,24.9,192.8,137.7,115.8,171.4,46.7,16.5,39,31.2,null,1.1,3.5,32.3],\"y\":[6.30881182466867,8.52992419042176,8.38085547307682,10.6066479292199,7.96932069435055,null,9.46266881579048,9.07023979759641,8.38121588701815,10.1898488421689,10.9385791252137,10.758088191882,8.62931123750333,10.0846045505965,9.85317033161763,7.17415702180554,9.49170929986023,8.80657365966086,10.7001215827459,8.18394962778588,7.14955673763465,11.4539630100402,8.00893037443067,7.7602473945212,8.71227360087351,8.89651997839502,9.27539542270893,null,10.385986713312,9.07603347784018,6.7037779461658,7.1000482058769,7.30708804974336,10.791730350859,8.09977169611914,null,11.2991870953016,5.93364306589175,6.66308032352879,9.55039021446055,9.03660351777116,8.88577804642723,7.2699813085854,7.62531106280079,6.0251629256367,9.17157002415743,7.44690050973015,9.62933663362922,8.82539333876025,null,10.3234624662976,10.0364016929494,11.0647630684713,null,8.65542670432035,8.90784113652276,8.43994851297957,8.02561798948246,8.09544518845762,9.04381063394029,9.91153762594947,8.45322147617273,6.43469922005144,null,null,8.24491287541651,10.7761147163269,10.6095670440446,null,9.08701502522759,6.6745031553326,8.4507675741913,10.7158630006919,7.5219946843681,null,9.97939285096023,10.8059180143124,9.00610560619377,8.0906073797198,null,6.86691110114396,6.38045085290232,9.07579827737062,7.08027542819549,7.6061610570602,9.72586010436267,10.7712251148447,7.58136214056314,8.36923899287234,8.69006984020304,8.50249536718338,11.3058652179768,11.4565605531483,10.4287312811534,10.4012851668547,8.37975939676959,10.7995808023904,null,8.08384004479648,9.31244633143297,7.09524808097351,7.49977861697756,10.3951990905822,6.90796833969762,7.51516060305545,9.69287965650615,8.44180171994647,6.99205836871611,6.19340173647502,8.61318150745542,null,9.81960367991734,11.5848552125718,6.12864692289002,6.26707189069791,9.36197513500012,8.64176287759047,6.6279129274692,10.1663711229728,7.4288417788681,9.1348453234067,9.14016848926877,8.16439758359388,12.2511631434174,8.30736870527666,8.89462506745524,null,8.04781786686865,6.33619694446231,7.29852949068417,8.5779022666637,6.72468671909238,10.8795801868517,null,10.5432930035698,7.45113613671164,6.3107194232771,7.72895197436046,8.58876589356957,11.417346009482,9.62125711504871,7.06334176241961,7.84347385986361,9.17069325215855,7.76080843428812,8.54926517297829,8.64565163513931,7.9996838862359,9.73774196294675,10.0331851890917,11.0008316984136,9.36433547325734,9.37472037973755,6.74410053271332,8.22637736301235,10.8375060593815,7.18209746731135,9.8725137247349,7.31337965739005,9.44135583405117,6.14952206968248,10.9393202952509,null,9.90288967798428,10.1565479330031,7.39785841178195,null,8.81703617256033,10.2527769055211,6.59432058387149,10.2955415450831,8.25470653472988,9.63004927067,8.91284074616402,8.80299518968459,7.57040874193413,8.86336995988682,10.9343250929137,11.2914358649754,null,null,7.04497355235111,6.88362305042045,8.71513098961245,6.7748143894923,6.54031768356785,9.52570690956431,8.29002725735166,9.63073445984275,null,6.8650489041171,8.04426072232906,10.6315311037386,10.5739518245108,10.8920798096704,9.50529981813926,7.80685943416513,7.8397512391051,9.5486941525913,7.66080025719052,null,6.45032620103665,7.35136552619679,6.96493475148219],\"text\":[\"Afghanistan<br />GDP Per Capita: $549<br />Vaccine Doses per 100 People: 5.1<br />Covid-19 Cases per 100 People: 0.4\",\"Albania<br />GDP Per Capita: $5,064<br />Vaccine Doses per 100 People: 56.7<br />Covid-19 Cases per 100 People: 5.5\",\"Algeria<br />GDP Per Capita: $4,363<br />Vaccine Doses per 100 People: 22.8<br />Covid-19 Cases per 100 People: 0.5\",\"Andorra<br />GDP Per Capita: $40,403<br />Vaccine Doses per 100 People: 120.9<br />Covid-19 Cases per 100 People: 19.4\",\"Angola<br />GDP Per Capita: $2,891<br />Vaccine Doses per 100 People: 7.5<br />Covid-19 Cases per 100 People: 0.2\",\"Anguilla<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Antigua & Barbuda<br />GDP Per Capita: $12,870<br />Vaccine Doses per 100 People: 81.1<br />Covid-19 Cases per 100 People: 2.1\",\"Argentina<br />GDP Per Capita: $8,693<br />Vaccine Doses per 100 People: 104.1<br />Covid-19 Cases per 100 People: 11.5\",\"Armenia<br />GDP Per Capita: $4,364<br />Vaccine Doses per 100 People: 11.3<br />Covid-19 Cases per 100 People: 8.4\",\"Aruba<br />GDP Per Capita: $26,631<br />Vaccine Doses per 100 People: 140.1<br />Covid-19 Cases per 100 People: NA\",\"Australia<br />GDP Per Capita: $56,307<br />Vaccine Doses per 100 People: 89.8<br />Covid-19 Cases per 100 People: 0.3\",\"Austria<br />GDP Per Capita: $47,009<br />Vaccine Doses per 100 People: 119.5<br />Covid-19 Cases per 100 People: 8\",\"Azerbaijan<br />GDP Per Capita: $5,593<br />Vaccine Doses per 100 People: 76<br />Covid-19 Cases per 100 People: 4.6\",\"Bahamas<br />GDP Per Capita: $23,971<br />Vaccine Doses per 100 People: 44<br />Covid-19 Cases per 100 People: 4.9\",\"Bahrain<br />GDP Per Capita: $19,019<br />Vaccine Doses per 100 People: 148.6<br />Covid-19 Cases per 100 People: 16.1\",\"Bangladesh<br />GDP Per Capita: $1,305<br />Vaccine Doses per 100 People: 21.4<br />Covid-19 Cases per 100 People: 0.9\",\"Barbados<br />GDP Per Capita: $13,249<br />Vaccine Doses per 100 People: 75.9<br />Covid-19 Cases per 100 People: 2.1\",\"Belarus<br />GDP Per Capita: $6,678<br />Vaccine Doses per 100 People: 32.8<br />Covid-19 Cases per 100 People: 5.2\",\"Belgium<br />GDP Per Capita: $44,361<br />Vaccine Doses per 100 People: 142<br />Covid-19 Cases per 100 People: 10.5\",\"Belize<br />GDP Per Capita: $3,583<br />Vaccine Doses per 100 People: 64.8<br />Covid-19 Cases per 100 People: 4.5\",\"Benin<br />GDP Per Capita: $1,274<br />Vaccine Doses per 100 People: 1.4<br />Covid-19 Cases per 100 People: 0.2\",\"Bermuda<br />GDP Per Capita: $94,274<br />Vaccine Doses per 100 People: 133.7<br />Covid-19 Cases per 100 People: NA\",\"Bhutan<br />GDP Per Capita: $3,008<br />Vaccine Doses per 100 People: 135.5<br />Covid-19 Cases per 100 People: 0.3\",\"Bolivia<br />GDP Per Capita: $2,345<br />Vaccine Doses per 100 People: 53.8<br />Covid-19 Cases per 100 People: 4.2\",\"Bosnia & Herzegovina<br />GDP Per Capita: $6,077<br />Vaccine Doses per 100 People: 32.3<br />Covid-19 Cases per 100 People: 6.6\",\"Botswana<br />GDP Per Capita: $7,307<br />Vaccine Doses per 100 People: 24.4<br />Covid-19 Cases per 100 People: 7\",\"Brazil<br />GDP Per Capita: $10,672<br />Vaccine Doses per 100 People: 101<br />Covid-19 Cases per 100 People: 9.9\",\"British Virgin Islands<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 106.6<br />Covid-19 Cases per 100 People: NA\",\"Brunei<br />GDP Per Capita: $32,402<br />Vaccine Doses per 100 People: 86.5<br />Covid-19 Cases per 100 People: 1\",\"Bulgaria<br />GDP Per Capita: $8,743<br />Vaccine Doses per 100 People: 35<br />Covid-19 Cases per 100 People: 6.9\",\"Burkina Faso<br />GDP Per Capita: $815<br />Vaccine Doses per 100 People: 0.8<br />Covid-19 Cases per 100 People: 0.1\",\"Cambodia<br />GDP Per Capita: $1,212<br />Vaccine Doses per 100 People: 125.9<br />Covid-19 Cases per 100 People: 0.6\",\"Cameroon<br />GDP Per Capita: $1,491<br />Vaccine Doses per 100 People: 1.7<br />Covid-19 Cases per 100 People: 0.3\",\"Canada<br />GDP Per Capita: $48,617<br />Vaccine Doses per 100 People: 143.6<br />Covid-19 Cases per 100 People: 4.1\",\"Cape Verde<br />GDP Per Capita: $3,294<br />Vaccine Doses per 100 People: 66.3<br />Covid-19 Cases per 100 People: 6.6\",\"Caribbean Netherlands<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Cayman Islands<br />GDP Per Capita: $80,756<br />Vaccine Doses per 100 People: 155.3<br />Covid-19 Cases per 100 People: NA\",\"Central African Republic<br />GDP Per Capita: $378<br />Vaccine Doses per 100 People: 2.3<br />Covid-19 Cases per 100 People: 0.2\",\"Chad<br />GDP Per Capita: $783<br />Vaccine Doses per 100 People: 0.6<br />Covid-19 Cases per 100 People: 0\",\"Chile<br />GDP Per Capita: $14,050<br />Vaccine Doses per 100 People: 158.6<br />Covid-19 Cases per 100 People: 8.6\",\"China<br />GDP Per Capita: $8,405<br />Vaccine Doses per 100 People: 153.8<br />Covid-19 Cases per 100 People: 0\",\"Colombia<br />GDP Per Capita: $7,228<br />Vaccine Doses per 100 People: 73.6<br />Covid-19 Cases per 100 People: 9.7\",\"Comoros<br />GDP Per Capita: $1,437<br />Vaccine Doses per 100 People: 38.5<br />Covid-19 Cases per 100 People: 0.5\",\"Congo - Brazzaville<br />GDP Per Capita: $2,049<br />Vaccine Doses per 100 People: 5.6<br />Covid-19 Cases per 100 People: 0.2\",\"Congo - Kinshasa<br />GDP Per Capita: $414<br />Vaccine Doses per 100 People: 0.1<br />Covid-19 Cases per 100 People: 0.1\",\"Costa Rica<br />GDP Per Capita: $9,620<br />Vaccine Doses per 100 People: 95.6<br />Covid-19 Cases per 100 People: 9.6\",\"Côte d’Ivoire<br />GDP Per Capita: $1,715<br />Vaccine Doses per 100 People: 6<br />Covid-19 Cases per 100 People: 0.2\",\"Croatia<br />GDP Per Capita: $15,204<br />Vaccine Doses per 100 People: 82.4<br />Covid-19 Cases per 100 People: 9.5\",\"Cuba<br />GDP Per Capita: $6,805<br />Vaccine Doses per 100 People: 145.9<br />Covid-19 Cases per 100 People: 6.6\",\"Curaçao<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 118.4<br />Covid-19 Cases per 100 People: NA\",\"Cyprus<br />GDP Per Capita: $30,438<br />Vaccine Doses per 100 People: 93.2<br />Covid-19 Cases per 100 People: 9.6\",\"Czechia<br />GDP Per Capita: $22,843<br />Vaccine Doses per 100 People: 109<br />Covid-19 Cases per 100 People: 15.7\",\"Denmark<br />GDP Per Capita: $63,880<br />Vaccine Doses per 100 People: 149.1<br />Covid-19 Cases per 100 People: 6.1\",\"Djibouti<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 6.6<br />Covid-19 Cases per 100 People: 1.2\",\"Dominica<br />GDP Per Capita: $5,741<br />Vaccine Doses per 100 People: 60.3<br />Covid-19 Cases per 100 People: 3.2\",\"Dominican Republic<br />GDP Per Capita: $7,390<br />Vaccine Doses per 100 People: 105.9<br />Covid-19 Cases per 100 People: 3.3\",\"Ecuador<br />GDP Per Capita: $4,628<br />Vaccine Doses per 100 People: 115.2<br />Covid-19 Cases per 100 People: 2.9\",\"Egypt<br />GDP Per Capita: $3,058<br />Vaccine Doses per 100 People: 11.2<br />Covid-19 Cases per 100 People: 0.3\",\"El Salvador<br />GDP Per Capita: $3,279<br />Vaccine Doses per 100 People: 108.1<br />Covid-19 Cases per 100 People: 1.5\",\"Equatorial Guinea<br />GDP Per Capita: $8,466<br />Vaccine Doses per 100 People: 26.1<br />Covid-19 Cases per 100 People: 0.7\",\"Estonia<br />GDP Per Capita: $20,162<br />Vaccine Doses per 100 People: 99.1<br />Covid-19 Cases per 100 People: 11.1\",\"Eswatini<br />GDP Per Capita: $4,690<br />Vaccine Doses per 100 People: 18.1<br />Covid-19 Cases per 100 People: 3.8\",\"Ethiopia<br />GDP Per Capita: $623<br />Vaccine Doses per 100 People: 2.9<br />Covid-19 Cases per 100 People: 0.3\",\"Falkland Islands<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Faroe Islands<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 147<br />Covid-19 Cases per 100 People: NA\",\"Fiji<br />GDP Per Capita: $3,808<br />Vaccine Doses per 100 People: 101.8<br />Covid-19 Cases per 100 People: 5.5\",\"Finland<br />GDP Per Capita: $47,864<br />Vaccine Doses per 100 People: 130.8<br />Covid-19 Cases per 100 People: 2.4\",\"France<br />GDP Per Capita: $40,521<br />Vaccine Doses per 100 People: 136.1<br />Covid-19 Cases per 100 People: 10.4\",\"French Polynesia<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 83.7<br />Covid-19 Cases per 100 People: NA\",\"Gabon<br />GDP Per Capita: $8,840<br />Vaccine Doses per 100 People: 6.6<br />Covid-19 Cases per 100 People: 1.2\",\"Gambia<br />GDP Per Capita: $792<br />Vaccine Doses per 100 People: 8.4<br />Covid-19 Cases per 100 People: 0.4\",\"Georgia<br />GDP Per Capita: $4,679<br />Vaccine Doses per 100 People: 41.3<br />Covid-19 Cases per 100 People: 15.8\",\"Germany<br />GDP Per Capita: $45,065<br />Vaccine Doses per 100 People: 125.7<br />Covid-19 Cases per 100 People: 4.9\",\"Ghana<br />GDP Per Capita: $1,848<br />Vaccine Doses per 100 People: 4.1<br />Covid-19 Cases per 100 People: 0.3\",\"Gibraltar<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 234.4<br />Covid-19 Cases per 100 People: NA\",\"Greece<br />GDP Per Capita: $21,577<br />Vaccine Doses per 100 People: 109.7<br />Covid-19 Cases per 100 People: 5.8\",\"Greenland<br />GDP Per Capita: $49,312<br />Vaccine Doses per 100 People: 130.7<br />Covid-19 Cases per 100 People: NA\",\"Grenada<br />GDP Per Capita: $8,153<br />Vaccine Doses per 100 People: 42.8<br />Covid-19 Cases per 100 People: 1.7\",\"Guatemala<br />GDP Per Capita: $3,264<br />Vaccine Doses per 100 People: 33.8<br />Covid-19 Cases per 100 People: 3\",\"Guernsey<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Guinea<br />GDP Per Capita: $960<br />Vaccine Doses per 100 People: 10.5<br />Covid-19 Cases per 100 People: 0.2\",\"Guinea-Bissau<br />GDP Per Capita: $590<br />Vaccine Doses per 100 People: 1.6<br />Covid-19 Cases per 100 People: 0.3\",\"Guyana<br />GDP Per Capita: $8,741<br />Vaccine Doses per 100 People: 65.1<br />Covid-19 Cases per 100 People: 3.6\",\"Haiti<br />GDP Per Capita: $1,188<br />Vaccine Doses per 100 People: 0.4<br />Covid-19 Cases per 100 People: 0.2\",\"Honduras<br />GDP Per Capita: $2,011<br />Vaccine Doses per 100 People: 46.8<br />Covid-19 Cases per 100 People: 3.5\",\"Hungary<br />GDP Per Capita: $16,745<br />Vaccine Doses per 100 People: 94.9<br />Covid-19 Cases per 100 People: 8.3\",\"Iceland<br />GDP Per Capita: $47,630<br />Vaccine Doses per 100 People: 147.2<br />Covid-19 Cases per 100 People: 3.1\",\"India<br />GDP Per Capita: $1,961<br />Vaccine Doses per 100 People: 54.5<br />Covid-19 Cases per 100 People: 2.4\",\"Indonesia<br />GDP Per Capita: $4,312<br />Vaccine Doses per 100 People: 42.7<br />Covid-19 Cases per 100 People: 1.5\",\"Iran<br />GDP Per Capita: $5,944<br />Vaccine Doses per 100 People: 41.7<br />Covid-19 Cases per 100 People: 6.3\",\"Iraq<br />GDP Per Capita: $4,927<br />Vaccine Doses per 100 People: 14.3<br />Covid-19 Cases per 100 People: 4.8\",\"Ireland<br />GDP Per Capita: $81,297<br />Vaccine Doses per 100 People: 141.3<br />Covid-19 Cases per 100 People: 7.4\",\"Isle of Man<br />GDP Per Capita: $94,519<br />Vaccine Doses per 100 People: 150.9<br />Covid-19 Cases per 100 People: NA\",\"Israel<br />GDP Per Capita: $33,817<br />Vaccine Doses per 100 People: 158.2<br />Covid-19 Cases per 100 People: 13\",\"Italy<br />GDP Per Capita: $32,902<br />Vaccine Doses per 100 People: 136.7<br />Covid-19 Cases per 100 People: 7.7\",\"Jamaica<br />GDP Per Capita: $4,358<br />Vaccine Doses per 100 People: 21.9<br />Covid-19 Cases per 100 People: 2.6\",\"Japan<br />GDP Per Capita: $49,000<br />Vaccine Doses per 100 People: 117.3<br />Covid-19 Cases per 100 People: 1.3\",\"Jersey<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Jordan<br />GDP Per Capita: $3,242<br />Vaccine Doses per 100 People: 65.9<br />Covid-19 Cases per 100 People: 7.9\",\"Kazakhstan<br />GDP Per Capita: $11,075<br />Vaccine Doses per 100 People: 69.7<br />Covid-19 Cases per 100 People: 4.9\",\"Kenya<br />GDP Per Capita: $1,206<br />Vaccine Doses per 100 People: 5.8<br />Covid-19 Cases per 100 People: 0.5\",\"Kiribati<br />GDP Per Capita: $1,808<br />Vaccine Doses per 100 People: 24.4<br />Covid-19 Cases per 100 People: 0\",\"Kuwait<br />GDP Per Capita: $32,702<br />Vaccine Doses per 100 People: 55.6<br />Covid-19 Cases per 100 People: 8.5\",\"Kyrgyzstan<br />GDP Per Capita: $1,000<br />Vaccine Doses per 100 People: 19.6<br />Covid-19 Cases per 100 People: 2.7\",\"Laos<br />GDP Per Capita: $1,836<br />Vaccine Doses per 100 People: 60.5<br />Covid-19 Cases per 100 People: 0.2\",\"Latvia<br />GDP Per Capita: $16,202<br />Vaccine Doses per 100 People: 82.3<br />Covid-19 Cases per 100 People: 7.8\",\"Lebanon<br />GDP Per Capita: $4,637<br />Vaccine Doses per 100 People: 38.6<br />Covid-19 Cases per 100 People: 9\",\"Lesotho<br />GDP Per Capita: $1,088<br />Vaccine Doses per 100 People: 9.4<br />Covid-19 Cases per 100 People: 0.7\",\"Liberia<br />GDP Per Capita: $490<br />Vaccine Doses per 100 People: 2.2<br />Covid-19 Cases per 100 People: 0.1\",\"Libya<br />GDP Per Capita: $5,504<br />Vaccine Doses per 100 People: 19.2<br />Covid-19 Cases per 100 People: 4.7\",\"Liechtenstein<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 115.9<br />Covid-19 Cases per 100 People: 8.9\",\"Lithuania<br />GDP Per Capita: $18,391<br />Vaccine Doses per 100 People: 117.6<br />Covid-19 Cases per 100 People: 11.1\",\"Luxembourg<br />GDP Per Capita: $107,458<br />Vaccine Doses per 100 People: 123.3<br />Covid-19 Cases per 100 People: 12.1\",\"Madagascar<br />GDP Per Capita: $459<br />Vaccine Doses per 100 People: 1<br />Covid-19 Cases per 100 People: 0.2\",\"Malawi<br />GDP Per Capita: $527<br />Vaccine Doses per 100 People: 5<br />Covid-19 Cases per 100 People: 0.3\",\"Malaysia<br />GDP Per Capita: $11,637<br />Vaccine Doses per 100 People: 121.2<br />Covid-19 Cases per 100 People: 6.2\",\"Maldives<br />GDP Per Capita: $5,663<br />Vaccine Doses per 100 People: 131.9<br />Covid-19 Cases per 100 People: 15.3\",\"Mali<br />GDP Per Capita: $756<br />Vaccine Doses per 100 People: 1.8<br />Covid-19 Cases per 100 People: 0.1\",\"Malta<br />GDP Per Capita: $26,014<br />Vaccine Doses per 100 People: 153.6<br />Covid-19 Cases per 100 People: 7\",\"Mauritania<br />GDP Per Capita: $1,684<br />Vaccine Doses per 100 People: 6.6<br />Covid-19 Cases per 100 People: 0.7\",\"Mauritius<br />GDP Per Capita: $9,273<br />Vaccine Doses per 100 People: 125.7<br />Covid-19 Cases per 100 People: 1\",\"Mexico<br />GDP Per Capita: $9,322<br />Vaccine Doses per 100 People: 71.9<br />Covid-19 Cases per 100 People: 2.7\",\"Moldova<br />GDP Per Capita: $3,514<br />Vaccine Doses per 100 People: 51.3<br />Covid-19 Cases per 100 People: 10.6\",\"Monaco<br />GDP Per Capita: $209,225<br />Vaccine Doses per 100 People: 125.5<br />Covid-19 Cases per 100 People: 8.3\",\"Mongolia<br />GDP Per Capita: $4,054<br />Vaccine Doses per 100 People: 133.1<br />Covid-19 Cases per 100 People: 8\",\"Montenegro<br />GDP Per Capita: $7,293<br />Vaccine Doses per 100 People: 67.8<br />Covid-19 Cases per 100 People: 19.8\",\"Montserrat<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Morocco<br />GDP Per Capita: $3,127<br />Vaccine Doses per 100 People: 98.3<br />Covid-19 Cases per 100 People: 2.4\",\"Mozambique<br />GDP Per Capita: $565<br />Vaccine Doses per 100 People: 7.7<br />Covid-19 Cases per 100 People: 0.5\",\"Myanmar (Burma)<br />GDP Per Capita: $1,478<br />Vaccine Doses per 100 People: 11.5<br />Covid-19 Cases per 100 People: 0.7\",\"Namibia<br />GDP Per Capita: $5,313<br />Vaccine Doses per 100 People: 13.9<br />Covid-19 Cases per 100 People: 5\",\"Nepal<br />GDP Per Capita: $833<br />Vaccine Doses per 100 People: 38.2<br />Covid-19 Cases per 100 People: 2.7\",\"Netherlands<br />GDP Per Capita: $53,081<br />Vaccine Doses per 100 People: 127<br />Covid-19 Cases per 100 People: 11.5\",\"New Caledonia<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 55.9<br />Covid-19 Cases per 100 People: NA\",\"New Zealand<br />GDP Per Capita: $37,922<br />Vaccine Doses per 100 People: 87.4<br />Covid-19 Cases per 100 People: 0.1\",\"Nicaragua<br />GDP Per Capita: $1,722<br />Vaccine Doses per 100 People: 11.1<br />Covid-19 Cases per 100 People: 0.2\",\"Niger<br />GDP Per Capita: $550<br />Vaccine Doses per 100 People: 2.6<br />Covid-19 Cases per 100 People: 0\",\"Nigeria<br />GDP Per Capita: $2,273<br />Vaccine Doses per 100 People: 2.8<br />Covid-19 Cases per 100 People: 0.1\",\"North Macedonia<br />GDP Per Capita: $5,371<br />Vaccine Doses per 100 People: 67.1<br />Covid-19 Cases per 100 People: 8.8\",\"Norway<br />GDP Per Capita: $90,885<br />Vaccine Doses per 100 People: 138.5<br />Covid-19 Cases per 100 People: 3.3\",\"Oman<br />GDP Per Capita: $15,082<br />Vaccine Doses per 100 People: 79<br />Covid-19 Cases per 100 People: 5.9\",\"Pakistan<br />GDP Per Capita: $1,168<br />Vaccine Doses per 100 People: 31.9<br />Covid-19 Cases per 100 People: 0.5\",\"Palestinian Territories<br />GDP Per Capita: $2,549<br />Vaccine Doses per 100 People: 34.8<br />Covid-19 Cases per 100 People: 7.6\",\"Panama<br />GDP Per Capita: $9,611<br />Vaccine Doses per 100 People: 114.8<br />Covid-19 Cases per 100 People: 10.7\",\"Papua New Guinea<br />GDP Per Capita: $2,347<br />Vaccine Doses per 100 People: 1.5<br />Covid-19 Cases per 100 People: 0.2\",\"Paraguay<br />GDP Per Capita: $5,163<br />Vaccine Doses per 100 People: 59.9<br />Covid-19 Cases per 100 People: 6.4\",\"Peru<br />GDP Per Capita: $5,685<br />Vaccine Doses per 100 People: 63.9<br />Covid-19 Cases per 100 People: 6.6\",\"Philippines<br />GDP Per Capita: $2,980<br />Vaccine Doses per 100 People: 36.1<br />Covid-19 Cases per 100 People: 2.1\",\"Poland<br />GDP Per Capita: $16,945<br />Vaccine Doses per 100 People: 97<br />Covid-19 Cases per 100 People: 7.6\",\"Portugal<br />GDP Per Capita: $22,770<br />Vaccine Doses per 100 People: 150.7<br />Covid-19 Cases per 100 People: 10.3\",\"Qatar<br />GDP Per Capita: $59,924<br />Vaccine Doses per 100 People: 160.2<br />Covid-19 Cases per 100 People: 8.2\",\"Romania<br />GDP Per Capita: $11,665<br />Vaccine Doses per 100 People: 51.2<br />Covid-19 Cases per 100 People: 5.8\",\"Russia<br />GDP Per Capita: $11,787<br />Vaccine Doses per 100 People: 59.7<br />Covid-19 Cases per 100 People: 4.9\",\"Rwanda<br />GDP Per Capita: $849<br />Vaccine Doses per 100 People: 21.8<br />Covid-19 Cases per 100 People: 0.7\",\"Samoa<br />GDP Per Capita: $3,738<br />Vaccine Doses per 100 People: 71.9<br />Covid-19 Cases per 100 People: 0\",\"San Marino<br />GDP Per Capita: $50,894<br />Vaccine Doses per 100 People: 138.2<br />Covid-19 Cases per 100 People: 15.9\",\"São Tomé & Príncipe<br />GDP Per Capita: $1,316<br />Vaccine Doses per 100 People: 26.1<br />Covid-19 Cases per 100 People: 1.3\",\"Saudi Arabia<br />GDP Per Capita: $19,390<br />Vaccine Doses per 100 People: 115<br />Covid-19 Cases per 100 People: 1.6\",\"Senegal<br />GDP Per Capita: $1,500<br />Vaccine Doses per 100 People: 10.4<br />Covid-19 Cases per 100 People: 0.4\",\"Seychelles<br />GDP Per Capita: $12,599<br />Vaccine Doses per 100 People: 147.9<br />Covid-19 Cases per 100 People: 20.5\",\"Sierra Leone<br />GDP Per Capita: $468<br />Vaccine Doses per 100 People: 2.8<br />Covid-19 Cases per 100 People: 0.1\",\"Singapore<br />GDP Per Capita: $56,349<br />Vaccine Doses per 100 People: 159.2<br />Covid-19 Cases per 100 People: 1.3\",\"Sint Maarten<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 118.9<br />Covid-19 Cases per 100 People: NA\",\"Slovakia<br />GDP Per Capita: $19,988<br />Vaccine Doses per 100 People: 84.6<br />Covid-19 Cases per 100 People: 7.3\",\"Slovenia<br />GDP Per Capita: $25,759<br />Vaccine Doses per 100 People: 94.7<br />Covid-19 Cases per 100 People: 13.2\",\"Solomon Islands<br />GDP Per Capita: $1,632<br />Vaccine Doses per 100 People: 13<br />Covid-19 Cases per 100 People: 0\",\"Somalia<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 2.1<br />Covid-19 Cases per 100 People: 0.1\",\"South Africa<br />GDP Per Capita: $6,748<br />Vaccine Doses per 100 People: 25.6<br />Covid-19 Cases per 100 People: 4.8\",\"South Korea<br />GDP Per Capita: $28,361<br />Vaccine Doses per 100 People: 104.2<br />Covid-19 Cases per 100 People: 0.5\",\"South Sudan<br />GDP Per Capita: $731<br />Vaccine Doses per 100 People: 0.6<br />Covid-19 Cases per 100 People: 0.1\",\"Spain<br />GDP Per Capita: $29,600<br />Vaccine Doses per 100 People: 144.9<br />Covid-19 Cases per 100 People: 10.4\",\"Sri Lanka<br />GDP Per Capita: $3,846<br />Vaccine Doses per 100 People: 110.5<br />Covid-19 Cases per 100 People: 2.2\",\"St. Kitts & Nevis<br />GDP Per Capita: $15,215<br />Vaccine Doses per 100 People: 87.8<br />Covid-19 Cases per 100 People: 2.8\",\"St. Lucia<br />GDP Per Capita: $7,427<br />Vaccine Doses per 100 People: 35.1<br />Covid-19 Cases per 100 People: 4.4\",\"St. Vincent & Grenadines<br />GDP Per Capita: $6,654<br />Vaccine Doses per 100 People: 29<br />Covid-19 Cases per 100 People: 2.2\",\"Sudan<br />GDP Per Capita: $1,940<br />Vaccine Doses per 100 People: 2.9<br />Covid-19 Cases per 100 People: 0.1\",\"Suriname<br />GDP Per Capita: $7,068<br />Vaccine Doses per 100 People: 63.2<br />Covid-19 Cases per 100 People: 5.9\",\"Sweden<br />GDP Per Capita: $56,068<br />Vaccine Doses per 100 People: 128.1<br />Covid-19 Cases per 100 People: 11\",\"Switzerland<br />GDP Per Capita: $80,132<br />Vaccine Doses per 100 People: 115.1<br />Covid-19 Cases per 100 People: 9.4\",\"Syria<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 2.3<br />Covid-19 Cases per 100 People: 0.2\",\"Taiwan<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Tajikistan<br />GDP Per Capita: $1,147<br />Vaccine Doses per 100 People: 36.1<br />Covid-19 Cases per 100 People: 0.2\",\"Tanzania<br />GDP Per Capita: $976<br />Vaccine Doses per 100 People: 0.6<br />Covid-19 Cases per 100 People: 0\",\"Thailand<br />GDP Per Capita: $6,094<br />Vaccine Doses per 100 People: 57.7<br />Covid-19 Cases per 100 People: 2\",\"Timor-Leste<br />GDP Per Capita: $876<br />Vaccine Doses per 100 People: 46.7<br />Covid-19 Cases per 100 People: 1.4\",\"Togo<br />GDP Per Capita: $693<br />Vaccine Doses per 100 People: 7.9<br />Covid-19 Cases per 100 People: 0.3\",\"Trinidad & Tobago<br />GDP Per Capita: $13,708<br />Vaccine Doses per 100 People: 71.3<br />Covid-19 Cases per 100 People: 3.4\",\"Tunisia<br />GDP Per Capita: $3,984<br />Vaccine Doses per 100 People: 58.5<br />Covid-19 Cases per 100 People: 5.9\",\"Turkey<br />GDP Per Capita: $15,226<br />Vaccine Doses per 100 People: 122.1<br />Covid-19 Cases per 100 People: 8\",\"Turks & Caicos Islands<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: 131.4<br />Covid-19 Cases per 100 People: NA\",\"Uganda<br />GDP Per Capita: $958<br />Vaccine Doses per 100 People: 3.1<br />Covid-19 Cases per 100 People: 0.3\",\"Ukraine<br />GDP Per Capita: $3,116<br />Vaccine Doses per 100 People: 24.9<br />Covid-19 Cases per 100 People: 5.5\",\"United Arab Emirates<br />GDP Per Capita: $41,420<br />Vaccine Doses per 100 People: 192.8<br />Covid-19 Cases per 100 People: 7.4\",\"United Kingdom<br />GDP Per Capita: $39,103<br />Vaccine Doses per 100 People: 137.7<br />Covid-19 Cases per 100 People: 10.8\",\"United States<br />GDP Per Capita: $53,749<br />Vaccine Doses per 100 People: 115.8<br />Covid-19 Cases per 100 People: 12.6\",\"Uruguay<br />GDP Per Capita: $13,431<br />Vaccine Doses per 100 People: 171.4<br />Covid-19 Cases per 100 People: 11.1\",\"Uzbekistan<br />GDP Per Capita: $2,457<br />Vaccine Doses per 100 People: 46.7<br />Covid-19 Cases per 100 People: 0.5\",\"Vanuatu<br />GDP Per Capita: $2,540<br />Vaccine Doses per 100 People: 16.5<br />Covid-19 Cases per 100 People: 0\",\"Venezuela<br />GDP Per Capita: $14,026<br />Vaccine Doses per 100 People: 39<br />Covid-19 Cases per 100 People: 1.2\",\"Vietnam<br />GDP Per Capita: $2,123<br />Vaccine Doses per 100 People: 31.2<br />Covid-19 Cases per 100 People: 0.6\",\"Wallis & Futuna<br />GDP Per Capita: NA<br />Vaccine Doses per 100 People: NA<br />Covid-19 Cases per 100 People: NA\",\"Yemen<br />GDP Per Capita: $633<br />Vaccine Doses per 100 People: 1.1<br />Covid-19 Cases per 100 People: 0\",\"Zambia<br />GDP Per Capita: $1,558<br />Vaccine Doses per 100 People: 3.5<br />Covid-19 Cases per 100 People: 1.1\",\"Zimbabwe<br />GDP Per Capita: $1,059<br />Vaccine Doses per 100 People: 32.3<br />Covid-19 Cases per 100 People: 0.9\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(190,190,190,1)\",\"opacity\":0.55,\"size\":[6.41926410999526,13.5679326667618,6.73084274435161,22.1631653745396,5.64610317477088,null,9.82792383876754,17.9335379599316,15.87632011848,null,6.06560647146759,15.5847883002411,12.7313097375516,13.0186054873456,20.5267785155365,7.73913238546532,9.82792383876754,13.2972330471862,17.3041527953489,12.6334731149446,5.64610317477088,null,6.06560647146759,12.3332516084314,14.5021881180346,14.8223378228178,16.9120510863381,null,7.95331752093908,14.7431768719833,5.09939583452519,7.01253136164397,6.06560647146759,12.2308081039362,14.5021881180346,null,null,5.64610317477088,3.77952755905512,16.0194824100724,3.77952755905512,16.7787225212617,6.73084274435161,5.64610317477088,5.09939583452519,16.7115427694105,5.64610317477088,16.6440122022995,14.5021881180346,null,16.7115427694105,20.3174296491328,14.0880283297847,8.35168538388007,11.2458300219182,11.361593552671,10.8872357461698,6.06560647146759,8.8913554091382,7.27157077931261,17.6852027087826,11.9157420384373,6.06560647146759,null,null,13.5679326667618,10.2455351642328,17.239595743043,null,8.35168538388007,6.41926410999526,20.3700145261573,13.0186054873456,6.06560647146759,null,13.831344874663,null,9.22148387072004,11.0087438331591,null,5.64610317477088,6.06560647146759,11.6987372118755,5.64610317477088,11.5879735799181,15.8040998159449,11.1282431068473,10.2455351642328,8.8913554091382,14.2556572198276,12.923843208705,15.1334637742993,null,18.8283412796446,15.3613246723536,10.5095616510491,8.53838030312068,null,15.5107733966801,13.0186054873456,6.73084274435161,3.77952755905512,15.9481118025219,10.6377642962925,5.64610317477088,15.4362885430593,16.300897444707,7.27157077931261,5.09939583452519,12.8280885737049,16.2311399666398,17.6852027087826,18.2980785892259,5.64610317477088,6.06560647146759,14.1721807527648,20.1053964940499,5.09939583452519,14.8223378228178,7.27157077931261,7.95331752093908,10.6377642962925,17.3684031581173,15.8040998159449,15.5847883002411,22.3517204395225,null,10.2455351642328,6.73084274435161,7.27157077931261,13.1124056376339,10.6377642962925,17.9335379599316,null,5.09939583452519,5.64610317477088,3.77952755905512,5.09939583452519,16.1609894793667,11.361593552671,13.9176281509287,6.73084274435161,15.2858724221738,17.4323511612035,5.64610317477088,14.3384737628157,14.5021881180346,9.82792383876754,15.2858724221738,17.1747275670061,15.7314431250458,13.831344874663,13.0186054873456,7.27157077931261,3.77952755905512,20.4224332569848,8.53838030312068,9.05900066093539,6.41926410999526,22.6771653543307,5.09939583452519,8.53838030312068,null,15.0564870479972,18.943659546287,3.77952755905512,5.09939583452519,12.923843208705,6.73084274435161,5.09939583452519,17.239595743043,9.9702585192109,10.7636139995701,12.5345432439104,9.9702585192109,5.09939583452519,13.9176281509287,17.622422816376,16.5761252659333,5.64610317477088,null,5.64610317477088,3.77952755905512,9.6821579296481,8.71802244153629,6.06560647146759,11.4756159808535,13.9176281509287,15.5847883002411,null,6.06560647146759,13.5679326667618,15.1334637742993,17.49600103353,18.5950122064986,17.6852027087826,6.73084274435161,3.77952755905512,8.35168538388007,7.01253136164397,null,3.77952755905512,8.15703540148278,7.73913238546532],\"symbol\":\"circle\",\"line\":{\"width\":1.88976377952756,\"color\":\"rgba(190,190,190,1)\"}},\"hoveron\":\"points\",\"name\":\"Not Serbia\",\"legendgroup\":\"Not Serbia\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null},{\"x\":[89.6],\"y\":[8.88148345327468],\"text\":\"Serbia<br />GDP Per Capita: $7,197<br />Vaccine Doses per 100 People: 89.6<br />Covid-19 Cases per 100 People: 12\",\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"autocolorscale\":false,\"color\":\"rgba(255,192,203,1)\",\"opacity\":0.55,\"size\":18.2379601072631,\"symbol\":\"circle\",\"line\":{\"width\":1.88976377952756,\"color\":\"rgba(255,192,203,1)\"}},\"hoveron\":\"points\",\"name\":\"Serbia\",\"legendgroup\":\"Serbia\",\"showlegend\":true,\"xaxis\":\"x\",\"yaxis\":\"y\",\"hoverinfo\":\"text\",\"frame\":null}],\"layout\":{\"margin\":{\"t\":40.8401826484018,\"r\":7.30593607305936,\"b\":37.2602739726027,\"l\":37.2602739726027},\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187},\"title\":{\"text\":\"Country Vaccine Doses vs Income\",\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":17.5342465753425},\"x\":0,\"xref\":\"paper\"},\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"type\":\"linear\",\"autorange\":false,\"range\":[-11.615,246.115],\"tickmode\":\"array\",\"ticktext\":[\"0\",\"50\",\"100\",\"150\",\"200\"],\"tickvals\":[0,50,100,150,200],\"categoryorder\":\"array\",\"categoryarray\":[\"0\",\"50\",\"100\",\"150\",\"200\"],\"nticks\":null,\"ticks\":\"\",\"tickcolor\":null,\"ticklen\":3.65296803652968,\"tickwidth\":0,\"showticklabels\":true,\"tickfont\":{\"color\":\"rgba(77,77,77,1)\",\"family\":\"\",\"size\":11.689497716895},\"tickangle\":-0,\"showline\":false,\"linecolor\":null,\"linewidth\":0,\"showgrid\":true,\"gridcolor\":\"rgba(235,235,235,1)\",\"gridwidth\":0.66417600664176,\"zeroline\":false,\"anchor\":\"y\",\"title\":{\"text\":\"# Vaccine Doses per 100 People\",\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187}},\"hoverformat\":\".2f\"},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"type\":\"linear\",\"autorange\":false,\"range\":[5.61776706201546,12.5670391472937],\"tickmode\":\"array\",\"ticktext\":[\"6\",\"8\",\"10\",\"12\"],\"tickvals\":[6,8,10,12],\"categoryorder\":\"array\",\"categoryarray\":[\"6\",\"8\",\"10\",\"12\"],\"nticks\":null,\"ticks\":\"\",\"tickcolor\":null,\"ticklen\":3.65296803652968,\"tickwidth\":0,\"showticklabels\":true,\"tickfont\":{\"color\":\"rgba(77,77,77,1)\",\"family\":\"\",\"size\":11.689497716895},\"tickangle\":-0,\"showline\":false,\"linecolor\":null,\"linewidth\":0,\"showgrid\":true,\"gridcolor\":\"rgba(235,235,235,1)\",\"gridwidth\":0.66417600664176,\"zeroline\":false,\"anchor\":\"x\",\"title\":{\"text\":\"Log Scale GDP per Capita\",\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":14.6118721461187}},\"hoverformat\":\".2f\"},\"shapes\":[{\"type\":\"rect\",\"fillcolor\":null,\"line\":{\"color\":null,\"width\":0,\"linetype\":[]},\"yref\":\"paper\",\"xref\":\"paper\",\"x0\":0,\"x1\":1,\"y0\":0,\"y1\":1}],\"showlegend\":false,\"legend\":{\"bgcolor\":null,\"bordercolor\":null,\"borderwidth\":0,\"font\":{\"color\":\"rgba(0,0,0,1)\",\"family\":\"\",\"size\":11.689497716895},\"y\":0.939099409448819},\"annotations\":[],\"hovermode\":\"closest\",\"barmode\":\"relative\"},\"config\":{\"doubleClick\":\"reset\",\"showSendToCloud\":false,\"displayModeBar\":false},\"source\":\"A\",\"attrs\":{\"44cc33e334d2\":{\"x\":{},\"y\":{},\"colour\":{},\"size\":{},\"alpha\":{},\"text\":{},\"type\":\"scatter\"}},\"cur_data\":\"44cc33e334d2\",\"visdat\":{\"44cc33e334d2\":[\"function (y) \",\"x\"]},\".hideLegend\":true,\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\",\"plotly_sunburstclick\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}\r\nUnfortunately this plot shows that % of the Population Vaccinated is more strongly related to the GDP per capita than number of Covid-19 cases per capita. This means that despite need, the richer countries get first pick and can buy their herd immunity. Serbia is not doing too badly as far as the middle income countries go, and it is certainly ahead of the trend for its income level. It just goes to show that getting a diverse range of vaccines can be helpful in more quickly vaccinating the population, despite being less financially well off than other countries.\r\nConcluding Remarks\r\nGoogle search results don’t align with vaccine numbers and I don’t know why I thought they would. Also Serbia is doing well with vaccines, so lets give the entire country a high-5.\r\nReferences\r\nErich Neuwirth (2014). RColorBrewer: ColorBrewer Palettes. R package version 1.1-2. https://CRAN.R-project.org/package=RColorBrewer\r\nJoachim Gassen (2021). tidycovid19: Download, Tidy and Visualize Covid-19 Related Data. R package version 0.0.0.9000.\r\nJovana Stanisljevic (11 May 2021), Small countries and Covid-19 vaccination: the example of Serbia. The Conversation. Accessed 15 September 2021.\r\nJim Hester (2020). glue: Interpreted String Literals. R package version 1.4.2. https://CRAN.R-project.org/package=glue\r\nC. Sievert. Interactive Web-Based Data Visualization with R, plotly, and shiny. Chapman and Hall/CRC Florida, 2020.\r\nWickham et al., (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686, https://doi.org/10.21105/joss.01686\r\n\r\n\r\n\r\n",
    "preview": "posts/2021-09-15-blog-post-2/blog-post-2_files/figure-html5/unnamed-chunk-1-1.png",
    "last_modified": "2021-09-17T23:29:01+10:00",
    "input_file": "blog-post-2.knit.md"
  },
  {
    "path": "posts/2021-09-04-blog-post-1/",
    "title": "Using Ecuador to Show My Mum the Effectiveness Of Vaccines",
    "description": "Watch me comb through data full of missing and nonsensical values to try and show my mother that lockdowns and vaccines are not pointless. Probably.",
    "author": [
      {
        "name": "Harriet Mason",
        "url": {}
      }
    ],
    "date": "2021-09-08",
    "categories": [],
    "contents": "\r\nThe Anti-Vaccine Rhetoric\r\nUnsurprisingly, my mum has been really anti-vaccine with all the Covid-19 stuff. In an effort to show that I am willing to listen to her perspective, I have watched 30 minutes of anti-vax videos over the past week and I would be lying if I said it was enjoyable. One of them was a 10 minute rant by some random guy in a Barbados town hall meeting who was talking about how Covid-19 was a man-made bio-weapon by the Chinese government. Ecuador does not have very strong data, but even crunching their numbers (there are a lot of NA values) I think I can disprove a few of the claims in the anti-vax dialogue. Ultimately a lot of the skepticism rhetoric centres around the view that the lockdowns are exessive and the vaccines are ineffective, and so, using the Ecuadorian data, we are going to check these two claims.\r\nEffectiveness of Lockdowns\r\nThe Data\r\nTo assess the effectiveness of the lock downs we need a few factors. Some measure of the strictness of the lockdown, a measure of whether or not these restrictions were followed, and a measure of the number of daily cases.\r\nCheck if restrictions are being followed with Google Mobility Data. The variables “residential” and “non-residential” are measures of the percentage change in mobility (as reported by google) when compared to the baseline period of Jan 3 – Feb 6, 2020. Where mobility is a measure of the number of people visiting the locations in that category and the duration of these visits. The “non-residential” variable is an average of the parks, retail, groceries, transit, and related mobility, “residential” is just for people spending time in residential buildings (such as their home). Since people spent most of their time at home prior to the pandemic, the “residential” and “non-residential” variables are not directly comparable.\r\nMeasure of lockdown strictness with University of Oxford Government Response Tracker Data. This gives us the stringency_index variable. This is a numeric score that summarises the strictness of closures and lockdowns.\r\nCheck case reports with Johns Hopkins University Case Data. This gives us the “cases” variable which is simply a summary of the reported cases. There is an issue in the Ecuador reporting where there are 4 days which account for a change in -9000 cases. It is impossible for there to be negative cases and so this is likely a correction for earlier mistakes in the data. Rather than average them over, there is a large unexplained spike very early in the dataset, I assumed this negative value was a correction for that and so I cancelled them out.\r\nThe Analysis\r\nSince the point of lockdowns is to reduce the number of cases, we are going to see how the lockdown intervention measures reduced the mobility and in turn, the number of cases in Ecuador.\r\n\r\n\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#bzrqlukxhp .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#bzrqlukxhp .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#bzrqlukxhp .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bzrqlukxhp .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#bzrqlukxhp .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#bzrqlukxhp .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#bzrqlukxhp .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#bzrqlukxhp .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bzrqlukxhp .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#bzrqlukxhp .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#bzrqlukxhp .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#bzrqlukxhp .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#bzrqlukxhp .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#bzrqlukxhp .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bzrqlukxhp .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#bzrqlukxhp .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#bzrqlukxhp .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bzrqlukxhp .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#bzrqlukxhp .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#bzrqlukxhp .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#bzrqlukxhp .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#bzrqlukxhp .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#bzrqlukxhp .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#bzrqlukxhp .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#bzrqlukxhp .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#bzrqlukxhp .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#bzrqlukxhp .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\nMonthly Summary of Lockdown Effectiveness\r\n    Comparison of Covid-19 cases, population mobility, and lockdown restrictions averaged across each month\r\n    Date(Year-Month)\r\n      New Confirmed Cases\r\n      Residential Mobility  (% increase since 2020-01)\r\n      Non-residential Mobility  (% increas since 2020-01)\r\n      Oxford NPI Stringency Index\r\n    2020-02\r\n0\r\n2\r\n−4\r\n62020-03\r\n2,240\r\n19\r\n−39\r\n542020-04\r\n11,828\r\n35\r\n−75\r\n942020-05\r\n17,277\r\n29\r\n−61\r\n872020-06\r\n17,334\r\n22\r\n−40\r\n822020-07\r\n28,923\r\n20\r\n−35\r\n792020-08\r\n28,412\r\n18\r\n−31\r\n752020-09\r\n31,233\r\n16\r\n−25\r\n612020-10\r\n31,145\r\n14\r\n−19\r\n522020-11\r\n24,493\r\n14\r\n−19\r\n532020-12\r\n19,827\r\n13\r\n−12\r\n622021-01\r\n38,316\r\n13\r\n−23\r\n702021-02\r\n35,327\r\n10\r\n−18\r\n692021-03\r\n42,600\r\n9\r\n−13\r\n602021-04\r\n53,107\r\n13\r\n−16\r\n682021-05\r\n44,175\r\n13\r\n−15\r\n732021-06\r\n32,467\r\n8\r\n2\r\n592021-07\r\n28,868\r\n7\r\n9\r\n612021-08\r\n13,829\r\n6\r\n13\r\n632021-09\r\n945\r\n8\r\n13\r\n66\r\n\r\nFrom this plot and table, we can see that while the restrictions were effective for a short period, this did not last. At the begining of the pandemic the citizen of Ecuador followed restrictions and stayed home, which is indicated by the higher residential mobility, lower non-residential mobility. This led to a decrease in cases. Unfortunately, this data shows that if the lockdown is strict but not managable (either because people need to work due to a lack of government support or the sheer duration of the lockdown) citizens will not follow. There is a slow increase in population mobility despite the restrictions staying the same, and obviously it leads to an increase in cases. Ultimately it seems that while the lockdown was an effective short term solution, it was not viable for the population to follow in the long run.\r\nVaccine Effectiveness\r\nThe Data\r\nI can use the same data as before, however I will also add in a dataset that contains the vaccination rate.\r\n- The vaccination rate will be calculated using data from the Our World in Data data. The data gives total vaccinations given, and while the data has a large number of NA values, its total is equal to any I could find online, so it will be taken as correct.\r\nSince the vaccines also lessen the severity of Covid-19 symptoms, I will also record the reported deaths form the Johns Hopkins University Case Data.\r\nThe Analysis\r\n\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#wcxaldewlt .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#wcxaldewlt .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#wcxaldewlt .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wcxaldewlt .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#wcxaldewlt .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#wcxaldewlt .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#wcxaldewlt .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#wcxaldewlt .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wcxaldewlt .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wcxaldewlt .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#wcxaldewlt .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#wcxaldewlt .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wcxaldewlt .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#wcxaldewlt .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wcxaldewlt .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wcxaldewlt .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#wcxaldewlt .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wcxaldewlt .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wcxaldewlt .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wcxaldewlt .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#wcxaldewlt .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#wcxaldewlt .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#wcxaldewlt .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#wcxaldewlt .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#wcxaldewlt .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#wcxaldewlt .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#wcxaldewlt .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\nMonthly Summary of Vaccine Effectiveness\r\n    Comparison of Covid-19 cases, % of population vaccinated, and number of deaths reported each month\r\n    Date(Year-Month)\r\n      Percent of Required Doses for 100% Vaccination\r\n      Total New Confirmed Cases\r\n      Total New Confirmed Deaths\r\n    2020-03\r\n0.0\r\n2,182.0\r\n73.02020-04\r\n0.0\r\n11,828.0\r\n825.02020-05\r\n0.0\r\n14,164.0\r\n2,458.02020-06\r\n0.0\r\n17,334.0\r\n1,169.02020-07\r\n0.0\r\n28,923.0\r\n1,175.02020-08\r\n0.0\r\n28,412.0\r\n854.02020-09\r\n0.0\r\n23,280.0\r\n4,799.02020-10\r\n0.0\r\n31,145.0\r\n1,315.02020-11\r\n0.0\r\n24,493.0\r\n791.02020-12\r\n0.0\r\n19,827.0\r\n573.02021-01\r\n0.0\r\n38,316.0\r\n825.02021-02\r\n0.1\r\n35,327.0\r\n952.02021-03\r\n0.7\r\n42,600.0\r\n1,036.02021-04\r\n2.9\r\n53,107.0\r\n1,784.02021-05\r\n6.5\r\n44,175.0\r\n1,941.02021-06\r\n12.4\r\n32,467.0\r\n988.02021-07\r\n33.6\r\n28,868.0\r\n10,071.02021-08\r\n57.4\r\n13,829.0\r\n613.0\r\n\r\nWhile it is rather simple to see the effectiveness of the lockdowns in the previous example, the unreliable reporting of Ecuador means the effects of vaccinations are not as easy to see. The cases seem to have dropped from their peak with the higher vaccination rates, but lagged reporting means that the month with the highest deaths is when the vaccination rate is at 33%, due to deaths in prior months. Even with the weak data however, the later months show a decrease in deaths and cases (ignoring the 10,000 case spike), indicating we can still see the effectiveness of vaccines.\r\nConcluding Remarks\r\nStay home and also get vaccinated, especially if you are my 60 year old mother.\r\nReferences\r\nWickham et al., (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686, https://doi.org/10.21105/joss.01686\r\nGarrett Grolemund, Hadley Wickham (2011). Dates and Times Made Easy with lubridate. Journal of Statistical Software, 40(3), 1-25. URL https://www.jstatsoft.org/v40/i03/.\r\nErich Neuwirth (2014). RColorBrewer: ColorBrewer Palettes. R package version 1.1-2. https://CRAN.R-project.org/package=RColorBrewer\r\nRichard Iannone, Joe Cheng and Barret Schloerke (2021). gt: Easily Create Presentation-Ready Display Tables. R package version 0.3.1. https://CRAN.R-project.org/package=gt\r\nRami Krispin and Jarrett Byrnes (2021). coronavirus: The 2019 Novel Coronavirus COVID-19 (2019-nCoV) Dataset. R package version 0.3.3. https://github.com/RamiKrispin/coronavirus\r\nJoachim Gassen (2021). tidycovid19: Download, Tidy and Visualize Covid-19 Related Data. R package version 0.0.0.9000.\r\n\r\n\r\n\r\n",
    "preview": "posts/2021-09-04-blog-post-1/blog-post-1_files/figure-html5/table1-1.png",
    "last_modified": "2021-09-08T23:55:18+10:00",
    "input_file": {}
  }
]
